CN Patent

CN111465413A — 包含6-(2-羟基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮杂双环[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的制剂

Assigned to Rosso Oncology Co · Expires 2020-07-28 · 6y expired

What this patent protects

公开了6‑(2‑羟基‑2‑甲基丙氧基)‑4‑(6‑(6‑((6‑甲氧基吡啶‑3‑基)甲基)‑3,6‑二氮杂双环[3.1.1]庚‑3‑基)吡啶‑3‑基)吡唑并[1,5‑a]吡啶‑3‑甲腈或其药学上可接受的盐、无定型、多晶型或药物组合物(包括固体制剂或液体制剂)及其用于治疗可以用RET激酶抑制剂治疗的疾病和病症，例如RET相关的疾病和病症，例如增殖性病症例如癌症，包括血液学癌症和实体瘤，以及胃肠道病症例如IBS的用途。

USPTO Abstract

公开了6‑(2‑羟基‑2‑甲基丙氧基)‑4‑(6‑(6‑((6‑甲氧基吡啶‑3‑基)甲基)‑3,6‑二氮杂双环[3.1.1]庚‑3‑基)吡啶‑3‑基)吡唑并[1,5‑a]吡啶‑3‑甲腈或其药学上可接受的盐、无定型、多晶型或药物组合物(包括固体制剂或液体制剂)及其用于治疗可以用RET激酶抑制剂治疗的疾病和病症，例如RET相关的疾病和病症，例如增殖性病症例如癌症，包括血液学癌症和实体瘤，以及胃肠道病症例如IBS的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN111465413A
Jurisdiction
CN
Classification
—
Expires
2020-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Rosso Oncology Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.